Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT01543178 Completed - Clinical trials for Irritable Bowel Syndrome With Diarrhea

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

TARGET3
Start date: February 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the effectiveness and safety of repeat treatment with rifaximin 550 mg three times a day in patients with IBS with diarrhea who respond to initial treatment of rifaximin 550 mg three times a day.

NCT ID: NCT01542268 Not yet recruiting - Clinical trials for Irritable Bowel Syndrome

Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS)

IBS-PTX
Start date: March 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the therapeutics effectiveness of oral pentoxifylline treatment in patients with IBS.

NCT ID: NCT01541891 Completed - Dry Eye Syndrome Clinical Trials

Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome

PRO-148
Start date: October 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of PRO-148 ophthalmic solution compared with SYSTANE ® ophthalmic solution for the treatment of signs and symptoms of mild-to-moderate dry eye syndrome.

NCT ID: NCT01541566 Completed - Metabolic Syndrome Clinical Trials

Blood Pressure Control and Compliance to Treatment in Hypertensive Patients With Metabolic Syndrome: a Study Based on Home Blood Pressure Telemonitoring and Assessment of Psychological Determinants

TELEBPMET
Start date: November 2007
Phase: N/A
Study type: Observational

The purpose of this study is to assess whether, in patients at high cardiovascular risk (hypertension with metabolic syndrome), long-term (1-year) blood pressure control is most effective when based on home blood pressure telemonitoring and on the feedback to the patient by the doctor between visits, or when based only on blood pressure determination during quarterly office visits.

NCT ID: NCT01541280 Completed - Clinical trials for Acute Myeloid Leukemia

VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

VIDAZA-DLI
Start date: November 2011
Phase: Phase 2
Study type: Interventional

Patients included in the study with high risk acute myeloid leukemia or myelodysplastic syndrome as defined will receive an allogeneic transplantation conditioned by either myeloablative or reduced regimen. Following allogeneic transplantation, patients will receive a maintenance regimen combining chemotherapy with azacitidine (aza) and immunotherapy with donor lymphocyte infusion.

NCT ID: NCT01538147 Completed - Clinical trials for Restless Leg Syndrome

Restless Leg Syndrome and Severe Preeclampsia

Start date: August 1, 2017
Phase: N/A
Study type: Observational

Restless Leg Syndrome is a common but not well recognized central nervous system disorder. It is more prevalent during pregnancy and, if present before pregnancy, can develop an exacerbation of symptoms. In some of the hypothesis trying to explain this syndrome, the physiopathology can also explain hypertensive disorders of pregnancy. So far, no study has been done trying to link both disorders.

NCT ID: NCT01538082 Recruiting - Metabolic Syndrome Clinical Trials

Role of the Stress in the Development of the Metabolic Syndrome

STREX
Start date: December 2008
Phase: N/A
Study type: Observational

The purpose of this study is determine the incidence of metabolic syndrome (MetS) in people of high risk, of 40 or more years and attended in the Primary Care. Evaluating the association between anxiety, depression, quality of life and the vital stressful events, and the development of the metabolic syndrome in general population. Our hypothesis is that population of the cohort with bigger degree of stress will develop earlier the metabolic syndrome. If our hypothesis about the metabolic syndrome are demonstrated, it would allow establishing in a future interventions on these factors of risk to prevent or to decrease the incidence of this syndrome in the Primary Care.

NCT ID: NCT01537354 Withdrawn - Clinical trials for Respiratory Distress Syndrome

Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome

Start date: June 2012
Phase: N/A
Study type: Interventional

This is a null hypothesis study. The investigators hypothesize that there will be no difference in changes in dynamic compliance when measured at 15, 30, 45 and 60 minute intervals after administration of either surfactant and there will be no differences in the number of doses needed between the two surfactants in premature infants admitted to our NICU.

NCT ID: NCT01537042 Completed - Clinical trials for End-Stage Renal Disease

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

Start date: April 2012
Phase: Phase 3
Study type: Interventional

This is a sleep laboratory study to evaluate the efficacy and safety of Rotigotine in subjects with Restless Legs Syndrome and End-Stage Renal Disease requiring hemodialysis. The objectives are to demonstrate superiority of Rotigotine against Placebo as well as to investigate the effect of Rotigotine on quality of life and sleep.

NCT ID: NCT01535859 Completed - Clinical trials for Ovarian Hyperstimulation Syndrome

Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers

Start date: April 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether cabergoline is effective in reducing the incidence and severity of Ovarian Hyperstimulation Syndrome (OHSS), especially for severe cases; and to derive biomarkers for the risk of developing OHSS.